Investors Shouldn't Be Too Comfortable With Hester Biosciences' (NSE:HESTERBIO) Earnings

Despite posting some strong earnings, the market for Hester Biosciences Limited's (NSE:HESTERBIO) stock hasn't moved much. Our analysis suggests that shareholders have noticed something concerning in the numbers.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

The Impact Of Unusual Items On Profit

Importantly, our data indicates that Hester Biosciences' profit received a boost of ₹905m in unusual items, over the last year. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And, after all, that's exactly what the accounting terminology implies. Hester Biosciences had a rather significant contribution from unusual items relative to its profit to September 2026. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Hester Biosciences.

Our Take On Hester Biosciences' Profit Performance

As we discussed above, we think the significant positive unusual item makes Hester Biosciences' earnings a poor guide to its underlying profitability. As a result, we think it may well be the case that Hester Biosciences' underlying earnings power is lower than its statutory profit. But on the bright side, its earnings per share have grown at an extremely impressive rate over the last three years. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. While conducting our analysis, we found that Hester Biosciences has 2 warning signs and it would be unwise to ignore these.

This note has only looked at a single factor that sheds light on the nature of Hester Biosciences' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.